Effects of silodosin, darifenacin, and combination therapy for the treatment of ureteral stent related discomforts
DOI:
https://doi.org/10.18203/2349-2902.isj20213989Keywords:
Pain, Stents, UreterAbstract
Background: To evaluate the effect of silodosin, darifenacin and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.
Methods: A total of 150 patients underwent placement of a double-J ureteral stent after retrograde ureteroscopy for urinary stone disease. All patients received polyurethane double-J ureteral stents (4 Fr and length 26 cm), which were removed at a mean of around 14 days postoperatively. A total of 40 patients were given no medication (group 1), 39 patients were given silodosin 4 mg once daily (group 2), 40 patients were given darifenacin 7.5 mg once daily (group 3), and 31 patients were given a combination of two agents postoperatively (group 4). International prostate symptom score (IPSS) and visual analogue pain scale (VAPS) questionnaires were completed by each patient at 1st day postoperatively and on the day of stent removal.
Results: In the total group of patients, the mean age was 50.24±12.90 years. There was a significant difference in the IPSS total score between group 1 and groups 3 and 4. Group 4 also differed significantly from group 1 in the irritative subscore. The obstructive subscore differed between groups 2 and 4 and group 1. There was a statistically significant difference between group 1 and group 4 in the quality of life (QoL) score.
Conclusions: Combination therapy with silodosin and darifenacin improved both irritative and obstructive symptoms more than in the other groups. Combination therapy should be strongly considered for patients who complain of stent-related symptoms.
References
Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopi- cally. J Urol. 1967;97:840-4.
Chew BH, Knudsen BE, Denstedt JD. The use of stents in con- temporary urology. Curr Opin Urol. 2004;14:111-5.
Jeong H, Kwak C, Lee SE. Ureteric stenting after ureteroscopy for ureteric stones: a prospective randomized study assessing symptoms and complications. BJU Int. 2004;93:1032-4.
Joshi HB, Stainthorpe A, Keeley FX, MacDonagh R, Timoney AG. Indwelling ureteral stents: Evaluation of quality of life to aid outcome analysis. J Endourol. 2001;15:151-4.
Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol. 1993;7:137-40.
Haleblian G, Kijvikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: a systematic review. J Urol. 2008;179:424-30.
el-Faqih SR, Shamsuddin AB, Chakrabarti A, Atassi R, Kardar AH, Osman MK, et al. Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J Urol. 1991;146:1487-91.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symp- toms, quality of life and utility. J Urol. 2003;169:1065-9.
Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol. 2003;17:195-9.
Jeon SS, Choi YS, Hong JH. Determination of ideal stent length for endourologic surgery. J Endourol. 2007;21:906-10.
Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183:598-602.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008; 22:651-6.
Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol. 2009;181:170-6.
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating dou- ble-J stent-related symptoms? Urology. 2006;67:35-9.
Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res. 2009;37:147-52.
Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine ex- tended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009;23:1913-7.
Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded pla- cebo-controlled comparison of extended release oxybutynin ver- sus phenazopyridine for the management of postoperative ure- teral stent discomfort. Urology. 2008;71:792-5.
Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for pre- vention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth. 2006;96:377-80.
Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, et al. Stent position is more important than alpha-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol. 2010;51:636-41.
